Post-traumatic Headache Multidisciplinary Study (PTHMS)
The Effect of Multidisciplinary Intervention on Patients With Persistent Post-traumatic Headache
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Pharmacological interventions are candesartan, amitritylin and gabapentin depending on the headache phenotype. In total 3 visits spanned over 1 year
Education is conducted as group sessions of up to 10 patients by two specialist nurses 2 x 90 min Physiotherapy is conducted as group sessions of up to 5 patients by physiotherapists 8 x 60 min plus 2 individual sessions.
Psychology is conducted as group sessions of up to 10 patients by psychologist 3x60 min plus option of 1 individual session.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Glostrup, Denmark, 2600
- Danish Headache Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients with post-traumatic headache
-
Exclusion Criteria:
- Medication-overuse headache
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in headache days
Time Frame: 1 year
|
Headache days will be obtained via a validated questionaire
|
1 year
|
|
Rivermead post-concussion questionare score
Time Frame: 1 year
|
Rivermead is a validated questionaire to assess concussion symptoms
|
1 year
|
|
HADS-scores
Time Frame: 1 year
|
HADS = Hospital anxiety and depression scale.
A validated tool to assesss depression and anxiety symptoms
|
1 year
|
|
Self-perceived health
Time Frame: 1 year
|
based on EU-SILC validated question on self-perceived health ('How is your health in general?'), which contains five answering categories; 1) very good, 2) good, 3) fair, 4) bad, 5) very bad.
|
1 year
|
|
Level of physical activity
Time Frame: 1 year
|
Based on questionaire, where patients can choose: Low level of physical activity: primarily sedentary activities or light exercise at least 4 hours a week, or
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Headache Disorders
- Craniocerebral Trauma
- Trauma, Nervous System
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Headache Disorders, Secondary
- Brain Concussion
- Headache
- Post-Concussion Syndrome
- Post-Traumatic Headache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Central Nervous System Depressants
- Sensory System Agents
- Analgesics
- Neurotransmitter Agents
- Anti-Anxiety Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anticonvulsants
- Antimanic Agents
- Excitatory Amino Acid Agents
- Excitatory Amino Acid Antagonists
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Gabapentin
- Candesartan
- Candesartan cilexetil
Other Study ID Numbers
Other Study ID Numbers
- DanishHC180322
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-Concussion Syndrome
-
NCT07211919CompletedPost Concussive Syndrome | Anxiety Disorder Not Otherwise Specified | Post Concussion Symptoms | Post Concussion Syndrome | Post Concussive Syndrome, Chronic
-
NCT05173818CompletedConcussion Post Syndrome | Persistent Post-concussive Syndrome
-
NCT02643836WithdrawnConcussion | Post Concussive Syndrome
-
NCT02035579CompletedConcussion | Post-concussion Syndrome | Sports Injury
-
NCT05848193Not yet recruitingPost Concussion Syndrome
-
NCT06031662RecruitingPost Concussion Syndrome
-
NCT02118220CompletedPost Concussion Symptoms
Clinical Trials on Candesartan
-
NCT02006602Completed
-
NCT00573430CompletedNon-diabetic Nephropathy With Hypertension
-
NCT02006589Completed
-
NCT02254447CompletedCardiovascular Disease
-
NCT02166697Completed
-
NCT00360763Unknown
-
NCT00235287UnknownCardiovascular Diseases | Kidney Failure, Chronic
-
NCT00679484TerminatedChronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level